Document 0023
 DOCN  M9460023
 TI    [Chemotherapy for human immunodeficiency virus infection. Current status
       and perspectives]
 DT    9408
 AU    Dumontet C; Biron F; Boibieux A; Allaouchiche B; Peyramond D; Service de
       Maladies Infectieuses, Hopital de la Croix Rousse,; Lyon.
 SO    Rev Med Interne. 1992 Nov;13(6):460-4. Unique Identifier : AIDSLINE
       MED/94225098
 AB    The role of drugs inhibiting viral replication in patients infected with
       HIV has been confirmed. Until now only dideoxynucleosides, which are
       reverse transcriptase inhibitors, have demonstrated antiviral activity
       in humans. A number of compounds acting on other steps of the viral
       cycle are currently being evaluated and clinical trials are being
       performed. Some investigators are attempting to inhibit the binding of
       viral particles to target cells and their penetration into these by
       acting on the interaction between HIV ant the CD4 molecule. Another
       approach consists in the characterization of enzymatic activities which
       are specific of HIV, other than reverse transcriptase, such as
       ribonuclease H, integrase or protease, in order to prepare specific
       inhibitors. Attempts are made to inhibit retroviral gene expression and
       production of viral particles in infected cells. The development of new
       nucleoside analogues and drugs with mechanisms of action and toxicities
       different from those of zidovudine should allow in the near future
       combination chemotherapy of HIV infection.
 DE    Dideoxynucleosides/CLASSIFICATION/PHARMACOLOGY/*THERAPEUTIC USE  English
       Abstract  Human  HIV Infections/*DRUG THERAPY/MICROBIOLOGY
       Transcription, Genetic/DRUG EFFECTS  Virus Integration/DRUG EFFECTS
       Virus Replication/DRUG EFFECTS  JOURNAL ARTICLE  REVIEW  REVIEW,
       TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).